Cyclo Therapeutics Inc - Ordinary Shares - Class A

NASDAQ:CYTH  
5.26
-0.04 (-0.76%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)44.04M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$0.39 Million
Adjusted EPS-$0.36
See more estimates
10-Day MA$5.78
50-Day MA$6.51
200-Day MA$7.99
See more pivots

Cyclo Therapeutics Inc - Ordinary Shares - Class A Stock, NASDAQ:CYTH

6714 NW 16th Street, Suite B, Gainesville, Florida 32653
United States of America
Phone: +1.386.418.8060
Number of Employees: 8

Description

Cyclo Therapeutics, Inc. engages in the development of cyclodextrin-based biopharmaceuticals for the treatment of disease. Its product candidates include Trappsol Cyclo, which treats Neimann-Pick Type C disease. The firm focuses on the development and commercialization of innovative cyclodextrin-based products for the treatment of people with serious and life threatening rare diseases and medical conditions. The company was founded by Charles E. Rick Strattan on August 9, 1990 and is headquartered in Gainesville, FL.